NCT07181239View on ClinicalTrials.gov

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

April 30, 2030

Conditions
Multiple Myeloma (MM)
Interventions
DRUG

CM336 Injection

Specified dose on specified days

DRUG

Standard Of Care( SOC)

Specified dose on specified days

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY